ASCO 2025 – Exelixis’s son of Cabometyx improves
In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.
ASCO 2025 – vepdegestrant matches rival degraders
Any hopes of differentiation could come down to side effects.
ASCO 2025 – Trodelvy heads for the front line
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
ASCO 2025 – Dizal goes after the BTK leaders
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
ASCO 2025 – BioNTech’s latest Claudin6 effort falls short
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
ASCO 2025 – 3SBio reveals what Pfizer got for its $1.25bn
Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.
ASCO 2025 – zilo-V adds a patient death to its tox tally
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
Harmoni spoils Summit's pre-ASCO splash
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
ASCO 2025 – Braftovi breaks new ground
The Breakwater study hits on overall survival with "unprecedented" data.
